CMC Biologics and Harpoon Therapeutics have entered into an agreement for the development and manufacturing of HPN424, HPN536, and HPN217, representing three TriTAC molecules for the treatment of various human cancers.   Harpoon Therapeutics’ TriTAC molecules are half-life extended and designed to simultaneously bind to cancer cells and T-cells, triggering those T-cells to attack the targeted cancer cells. These molecules contain three binding domains: one domain binds a specific tumor t...